- Advertised plan
- $299; supply period and preparation require confirmation
- Subscription
- Not required according to the page
- Lab documents
- Sermorelin upload pending at source check
Start with the assessment offer
BRAVO1 Wellness presents sermorelin as a plan evaluated through physician review. The checked page advertises $299 and says a subscription is not required. Those are useful purchasing facts, but neither identifies a universal prescription, a fixed monthly supply or a particular route. The page leaves administration details to the clinical assessment rather than establishing them for every applicant.
This provider profile therefore treats the listing as an assessment-led plan. A prospective patient needs the proposed preparation and actual quantity before comparing it with a clearly labeled injectable vial or an oral product. We have not enrolled in the service or independently assessed its medical decision-making, fulfillment or follow-up performance.
Published laboratory information has a gap
The provider describes independent testing and maintains a laboratory-documentation page. At the time checked, the sermorelin entry said its upload was pending. A statement that testing is performed is different from a publicly inspectable report for the preparation or batch that might be dispensed. We cannot verify an unseen certificate from the marketing description alone.
Ask whether the dispensing pharmacy can supply relevant quality information and identify the product associated with it. A report should be read for what was actually tested, rather than treated as proof of every possible quality attribute. Public documentation can change, so the pending status describes this review's source check rather than a permanent judgment about the service.
A flat headline still needs a care budget
The absence of a mandatory subscription can matter to someone comparing recurring plans. It does not automatically establish that $299 pays for every visit, laboratory test or future refill. Request a written account of the services included, the supply period and any charges triggered by ongoing monitoring or a prescription change.
Clarify payment timing relative to clinician approval, what happens if treatment is not appropriate and how cancellation works before fulfillment. A non-subscription purchase may still have order-specific refund restrictions. Those terms belong alongside the medication details when deciding whether the initial offer matches the total commitment a patient is prepared to make.
Separate historical approval from the current offer
The page discusses sermorelin's FDA history. The historical Geref products and their regulatory record do not make a current compounded preparation FDA-approved. FDA does not review compounded drugs for safety, effectiveness and quality before marketing in the same way it reviews approved drugs. The status of the actual product should be clear in the consultation.
Adult wellness and aging claims also need evidence relevant to the proposed purpose and patient. Our assessment identifies a documented starting offer and a visible laboratory-documentation gap; it does not establish clinical benefit. The clinician should explain the rationale, uncertainties and follow-up plan before the commercial simplicity of a single headline price becomes the deciding factor.
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.